DSC Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

DSC Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-82,500	Closed	-$2.31M	–	60
2016 Q1	$2.31M	Buy	82,500 +17,500	+27%	+$382K	1.37%	20
2015 Q4	$2.32M	Sell	65,000 -25,000	-28%	-$881K	1.21%	23
2015 Q3	$2.98M	Buy	90,000 +25,000	+38%	+$1.04M	1.44%	22
2015 Q2	$2.72M	Hold	65,000	–	–	1.42%	18
2015 Q1	$2.12M	Buy	+65,000	New	+$2.23M	1.12%	25

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DSC Advisors's ACAD Position: Q2 2016 in Review

DSC Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2016, closing a stake of 82,500 shares — an estimated $2.31M sold.

DSC Advisors first reported a position in ACAD in Q1 2015 and held it in 5 quarters. The position peaked at $2.98M in Q3 2015. 227 funds tracked by Wall St. Rank hold ACAD as of Q2 2016.

DSC Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
DSC Advisors sold 82,500 Acadia Pharmaceuticals shares in Q2 2016, an estimated $2.31M.
DSC Advisors first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 5 quarters.
DSC Advisors's Acadia Pharmaceuticals position peaked at $2.98M in Q3 2015.
227 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2016.

Based on DSC Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.